# US 2016/0355600 A1 · Trispecific antibodies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0355600 A1
- Document ID: US20160355600A1
- Status: Published application
- Kind: A1
- Application number: 14/757,809
- Filed: 2015-12-22
- Published: 2016-12-08
- Earliest claimed: 2014-12-22
- Assignees: Xencor, Inc.
- Applicants: Xencor, Inc.
- Inventors: Gregory Moore; John Desjarlais; Seung Chu; Sung-Hyung Lee
- Web page: https://patentgrep.com/patent/US20160355600A1

## CPC

- C07K 16/2887: {against CD20}
- C07K 16/2803: {against the immunoglobulin superfamily}
- C07K 16/2809: {against the T-cell receptor (TcR)-CD3 complex}
- C07K 16/2815: {against CD8}
- C07K 16/2866: {against receptors for cytokines, lymphokines, interferons}
- C07K 16/2896: {against molecules with a "CD"-designation, not provided for elsewhere}
- C07K 2317/31: multispecific
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/60: characterized by non-natural combinations of immunoglobulin fragments
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/626: Diabody or triabody
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The invention provides trispecific antibodies that co-engage CD3, CD8 and a tumor target antigen.

## Claims

### Claim at position 1

-14. (canceled)

### Claim 15

A trispecific antibody comprising:
a) a first monomer comprising:
i) a first heavy chain comprising a first variant Fc domain and a first variable heavy domain;
ii) a first scFv domain; and
b) a second monomer comprising:
i) a second heavy chain comprising a second variant Fc domain and said first variable heavy domain;
ii) a second scFv domain; and
c) a light chain comprising a constant light domain and a variable light domain; wherein said first variable heavy domain and said variable light domain forms a first antigen binding domain that binds a first antigen, said first scFv domain forms a second antigen binding domain that binds a second antigen, and said second scFv domain forms a third antigen binding domain that binds a third antigen, and one of said binding domains binds CD8 and has a variable region comprising a variable region selected from the group consisting of a variable region comprising a variable heavy domain having the sequence of OKT8 H1 and a variable light domain having the sequence LL a variable region comprising a variable heavy domain having the sequence of OKT8 H2 and a variable light domain having the sequence LL a variable region comprising a variable heavy domain having the sequence of OKT8 H1 and a variable light domain having the sequence L2 and a variable region comprising a variable heavy domain having the sequence of 51.1 H1 and a variable light domain having the sequence L1.

### Claim at position 3

-53. (canceled)

### Claim 54 (depends on 15)

A nucleic acid composition comprising:
a) a first nucleic acid encoding said first monomer of claims 15;
b) a second nucleic acid encoding said second monomer of claim 15, respectively; and
c) a third nucleic acid encoding said light chain of claim 15.

### Claim 55 (depends on 54)

An expression vector composition comprising:
a) a first expression vector comprising said first nucleic acid of claim 54;
b) a second expression vector comprising said second nucleic acid of claim 54; and
c) a third expression vector comprising said third nucleic acid of claim 54.

### Claim 56 (depends on 54)

A host cell comprising the nucleic acid composition of claim 54.

### Claim 57 (depends on 55)

A host cell comprising the expression vector composition of claim 55.

### Claim 58 (depends on 15, 57)

A method of making a trispecific antibody according to claim 15 comprising culturing the host cell of claim 57 under conditions wherein said trispecific antibody is produced and recovering said antibody.

### Claim 59 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53)

A method of treating a patient in need thereof comprising administering a trispecific antibody according to any of claims 1 to 53 to said patient.

### Claim at position 10

-102. (canceled)
